ANRO (Alto Neuroscience) Short-Term Debt : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Short-Term Debt?

Alto Neuroscience's Short-Term Debt for the quarter that ended in Mar. 2025 was $0.00 Mil.

Alto Neuroscience's quarterly Short-Term Debt declined from Sep. 2024 ($3.53 Mil) to Dec. 2024 ($0.00 Mil) but then stayed the same from Dec. 2024 ($0.00 Mil) to Mar. 2025 ($0.00 Mil).

Alto Neuroscience Short-Term Debt Historical Data

The historical data trend for Alto Neuroscience's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Short-Term Debt Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Alto Neuroscience Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt	Get a 7-Day Free Trial						1.15	2.32	3.53	-	-

Alto Neuroscience Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Alto Neuroscience Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

650 Castro Street, Suite 450, Mountain View, CA, USA, 94041

Website

https://www.altoneuroscience.com

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.